	US 12,440,553 B2
	Multivalent carriers and related vaccine compositions
Alexander A. Cohen, Pasadena, CA (US); and Pamela J. Bjorkman, Altadena, CA (US)
Assigned to California Institute of Technology, Pasadena, CA (US)
Filed by California Institute of Technology, Pasadena, CA (US)
Filed on Nov. 10, 2021, as Appl. No. 17/523,813.
Claims priority of provisional application 63/112,495, filed on Nov. 11, 2020.
Prior Publication US 2022/0168414 A1, Jun. 2, 2022
Int. Cl. A61K 39/215 (2006.01); A61K 39/385 (2006.01); A61K 39/39 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01); C07K 14/165 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61K 39/385 (2013.01); A61K 39/39 (2013.01); A61P 31/14 (2018.01); A61P 37/04 (2018.01); C07K 14/165 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/70 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)]

29 Claims

1. A vaccine composition, comprising a multivalent carrier associated with a plurality of coronavirus antigens, wherein the plurality of coronavirus antigens comprises a first coronavirus antigen of a first coronavirus strain and a second coronavirus antigen of a second coronavirus strain that is different from the first coronavirus strain,

wherein the first coronavirus antigen and the second coronavirus antigen each comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12 and the amino acid sequences of the first and second coronavirus antigens are different from one another, and

wherein the multivalent carrier comprises a self-assembling nanoparticle.